NASDAQ:GOSS - Gossamer Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.50
  • Forecasted Upside: 125.52 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$7.76
▼ -0.88 (-10.19%)

This chart shows the closing price for GOSS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gossamer Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GOSS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GOSS

Analyst Price Target is $17.50
▲ +125.52% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Gossamer Bio in the last 3 months. The average price target is $17.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 125.52% upside from the last price of $7.76.

This chart shows the closing price for GOSS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Gossamer Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/19/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/17/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2022Cantor FitzgeraldReiterated RatingOverweightHigh
4/26/2022Raymond JamesLower Price TargetOutperform$19.00 ➝ $10.00High
4/26/2022BarclaysLower Price TargetOverweight$18.00 ➝ $12.00High
4/26/2022HC WainwrightLower Price Target$25.00 ➝ $20.00High
4/25/2022Piper SandlerLower Price Target$26.00 ➝ $15.00High
4/18/2022Raymond JamesInitiated CoverageOutperform$19.00High
4/6/2022UBS GroupInitiated CoverageBuy$19.00High
1/10/2022Sumitomo Mitsui Financial GroupUpgradeNeutral ➝ Outperform$24.00Low
1/10/2022CitigroupUpgradeNeutral ➝ Outperform$24.00Low
11/9/2021SVB LeerinkBoost Price TargetOutperform$15.00 ➝ $16.00High
10/18/2021Cantor FitzgeraldReiterated RatingOverweightLow
10/14/2021SVB LeerinkInitiated CoverageBuyMedium
9/20/2021Piper SandlerInitiated CoverageBuy$26.00Medium
8/10/2021SVB LeerinkLower Price TargetOutperform$19.00 ➝ $15.00High
5/9/2021Evercore ISIReiterated RatingBuy$23.00High
3/24/2021HC WainwrightReiterated RatingBuy$24.00 ➝ $25.00High
12/17/2020HC WainwrightReiterated RatingBuy$15.00 ➝ $24.00High
10/19/2020HC WainwrightLower Price TargetBuy$31.00 ➝ $15.00Medium
10/16/2020BarclaysLower Price TargetReduce ➝ Overweight$22.00 ➝ $18.00Low
10/13/2020SVB LeerinkLower Price TargetOutperform$36.00 ➝ $29.00High
10/13/2020Piper SandlerLower Price TargetOverweight$30.00 ➝ $23.00High
10/9/2020Cantor FitzgeraldLower Price TargetOverweight$33.00 ➝ $20.00High
9/22/2020HC WainwrightReiterated RatingBuy$31.00Low
7/14/2020Cantor FitzgeraldBoost Price TargetOverweight$25.00 ➝ $33.00High
6/29/2020HC WainwrightInitiated CoverageBuy$31.00High
5/20/2020SVB LeerinkBoost Price TargetPositive ➝ Outperform$27.00 ➝ $36.00Low
4/22/2020Piper SandlerInitiated CoverageOverweight$30.00High
2/27/2020BarclaysInitiated CoverageOverweight$21.00High
12/17/2019Cantor FitzgeraldReiterated RatingOverweight$34.00 ➝ $25.00High
12/6/2019Cantor FitzgeraldInitiated CoverageOverweight$34.00High
12/3/2019Bank of AmericaInitiated CoverageBuy$32.00Low
10/30/2019Berenberg BankInitiated CoverageBuy$31.00High
8/12/2019Evercore ISISet Price TargetBuy$30.00Medium
3/5/2019Evercore ISIInitiated CoverageOutperform$30.00High
3/5/2019SVB LeerinkInitiated CoverageOutperform$30.00High
3/5/2019BarclaysInitiated CoverageOverweight$27.00High
3/5/2019Bank of AmericaInitiated CoverageBuy$30.00High
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
10/21/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/18/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
5/19/2022

Current Sentiment

  • 1 very positive mentions
  • 11 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Gossamer Bio logo
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $7.76
Low: $7.72
High: $8.60

50 Day Range

MA: $8.46
Low: $6.41
High: $9.97

52 Week Range

Now: $7.76
Low: $6.28
High: $14.30

Volume

491,260 shs

Average Volume

786,348 shs

Market Capitalization

$598.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Gossamer Bio?

The following sell-side analysts have issued research reports on Gossamer Bio in the last year: Barclays PLC, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Piper Sandler, Raymond James, Sumitomo Mitsui Financial Group, Inc., SVB Leerink LLC, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for GOSS.

What is the current price target for Gossamer Bio?

0 Wall Street analysts have set twelve-month price targets for Gossamer Bio in the last year. Their average twelve-month price target is $17.50, suggesting a possible upside of 125.5%.
View the latest price targets for GOSS.

What is the current consensus analyst rating for Gossamer Bio?

Gossamer Bio currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GOSS will outperform the market and that investors should add to their positions of Gossamer Bio.
View the latest ratings for GOSS.

How do I contact Gossamer Bio's investor relations team?

Gossamer Bio's physical mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company's listed phone number is (858) 684-1300 and its investor relations email address is [email protected] The official website for Gossamer Bio is www.gossamerbio.com. Learn More about contacing Gossamer Bio investor relations.